Summary
4AB Chart
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed.1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer1 The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination NORTH CHICAGO, Ill. , June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy.
AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
AbbVie Inc. (NYSE:ABBV ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Director Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
AbbVie Inc. Dividends
 ABBV In 1 month Estimated | Quarterly | $1.64 Per Share |
| ABBV 1 month ago Paid | Quarterly | $1.64 Per Share |
| ABBV 4 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 7 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 10 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
AbbVie Inc. Earnings
| 23 Jul 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
| 30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
| 25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
| ABBV In 1 month Estimated | Quarterly | $1.64 Per Share |
| ABBV 1 month ago Paid | Quarterly | $1.64 Per Share |
| ABBV 4 months ago Paid | Quarterly | $1.64 Per Share |
| ABBV 7 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 10 months ago Paid | Quarterly | $1.55 Per Share |
| ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
| 23 Jul 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
| 30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
| 25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
AbbVie Inc. (4AB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has AbbVie Inc. ever had a stock split?
AbbVie Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XMUN Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
Overview
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.
Products and Services
- Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
- Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
- Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
- Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
- Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
- Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
- Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
- Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
- Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
- Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
- Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
- Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
- Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
- Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
- Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
- Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
- Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
- Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.
Contact Information
